Oh dear, King Zior has put me in the naughty corner. How will I cope?
Why would I change what I'm criticising when the very thing I'm criticising only gets worse?
It is surprising that a charting specialist - a completely objective discipline - is so subjective (delusional?) when it comes to assessing IMU's fundamentals. Fundamentals which have objectively trumped your technical analysis for more than two years.
The cheersquad will keep deluding themselves that the "fundamentals have only gotten stronger" and "IMU has only ever made positive announcements" even in the face of the jewel in IMU's crown for the past decade now being "de-prioritised". They will also delude themselves that all SP weakness is because of manipulators and shorters (who apparently have been bashing away on a daily basis for over two years). They will delude themselves that Hopper is better for a biotech than Hoos.
If you did go back to my posts, you will see that I was complimentary about the CF33 progress and particularly about IMU's first ever external endorsement of something it is doing (the FDA fast-track). But in spite of these two indisputably positive developments, we are seeing SP weakness. The SP weakness is occurring - as predicted - after the Board was left intact and the greedy self-awarded rewards hit a new, sickening high. And this was done at the very next opportunity after the remuneration strike. No strike this year .... imagine what level the remuneration will get to next year now that Hopper has been "endorsed".
With all this objective evidence, you still think that the Hopper / Leslie show is not the biggest drag on IMU value? CF33 and Professor Fong are probably going better and faster than anyone anticipated, yet not one unpaid fund manager or investment analyst covers the stock - even though it was in the ASX200 for two years.
Make all the personal attacks you like, but its not going to change the fact that with the current management team IMU is simply not considered investment-grade by the serious investment community.
Its not a matter of pessimism. I'm optimistic and hopeful that CF33 will be the cancer-buster that it potentially could be. I'm sure that if it is, IMU will sell for multiples of its current SP. But I'm realistic enough to acknowledge that if / when IMU sells, it will be for a fraction of what it could have with a more respectable management team.
As shareholders, we can't add value by advancing the science. However, we can add value by acknowledging the shortcomings of the management team and making an effort to change it. We failed to do so while Hopper engineered the removal of Axel Hoos. It was easy, the SP was going up. To waste an opportunity in the face of a decimated SP, and more and more evidence that poor management it diminishing the benefits of scientific advancement, is frustrating to say the least.
IMU Price at posting:
10.3¢ Sentiment: None Disclosure: Not Held
(20min delay)